immatics is developing cancer drugs that help to activate the self defense mechanisms of the human body.
Our goal is to support patients and physicians with new options in the fight against various cancers.
Our means are synthetic peptides that specifically activate specialized white blood cells of the patient’s immune system against cancer cells.
Our first product for the treatment of kidney cancer, IMA901, has entered a Europe-wide multi-center Phase II clinical trial in 2007. Our second product for the treatment of colorectal cancer, IMA910, has recently entered another large Phase I/II clinical trial and is now open for patient recruitment.
- -- 14 July 2008
immatics obtains important U.S. and European patents - Tuebingen, July 14, 2008 – immatics biotechnologies GmbH today announced that the company has obtained European ... read more
- -- 09 July 2008
immatics appoints Paul G. Higham as Chief Executive Officer - Tuebingen, July 9, 2008 – immatics biotechnologies GmbH today announced the appointment of Paul G. Higham as Chief ... read more
- -- 07 July 2008
immatics receives 3 research grants totaling 1.4 mn € to advance its early-stage cancer immunotherapy programs - Tuebingen, July 7, 2008 – immatics biotechnologies GmbH today announced that the company has received grants from ... read more
Renal cell cancer phase II clinical trial
Drug: Peptide-based renal cell cancer vaccine IMA901...read more
Participating countries: Germany, Austria, Switzerland, U.K., Spain, Bulgaria, Hungary, Poland, Romania, Slovakia
Colorectal cancer phase I/II clinical trial
Drug: Peptide-based colorectal cancer vaccine IMA910...read more
Participating countries: Germany, Belgium, U.K., Hungary, Serbia, Latvia, Poland, Romania